These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6536176)

  • 1. [Synthesis of mexiletine analogs].
    Xia L; Ni PZ; Ji M
    Yao Xue Xue Bao; 1984 Sep; 19(9):656-9. PubMed ID: 6536176
    [No Abstract]   [Full Text] [Related]  

  • 2. The development of mexiletine.
    Köppe HG
    Postgrad Med J; 1977; 53 Suppl 1():22-4. PubMed ID: 327456
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.
    Carocci A; Catalano A; Bruno C; Lentini G; Franchini C; De Bellis M; De Luca A; Conte Camerino D
    Chirality; 2010 Mar; 22(3):299-307. PubMed ID: 19544349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of mexiletine.
    Danneberg PB; Shelley JH
    Postgrad Med J; 1977; 53 Suppl 1():25-9. PubMed ID: 876950
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
    Catalano A; Desaphy JF; Lentini G; Carocci A; Di Mola A; Bruno C; Carbonara R; De Palma A; Budriesi R; Ghelardini C; Perrone MG; Colabufo NA; Conte Camerino D; Franchini C
    J Med Chem; 2012 Feb; 55(3):1418-22. PubMed ID: 22191686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereospecific synthesis of "para-hydroxymexiletine" and sodium channel blocking activity evaluation.
    Catalano A; Carocci A; Fracchiolla G; Franchini C; Lentini G; Tortorella V; De Luca A; De Bellis M; Desaphy JF; Conte Camerino D
    Chirality; 2004 Feb; 16(2):72-8. PubMed ID: 14712469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical study of the pharmacodynamic and toxicologic effects of the antiarrhythmic agent, mexiletine].
    Jezek L; Urbánková G; Gasparík J; Hudcovicová E; Nosál R; Hesek D; Rybár A; Mahrla Z
    Bratisl Lek Listy; 1986 Feb; 85(2):152-9. PubMed ID: 3955401
    [No Abstract]   [Full Text] [Related]  

  • 8. [Synthesis and antihypertensive activity of some phenoxyalkylamine compounds].
    Xia L; Ni PZ; Song W; Liu GQ; Qian JQ; Li P; Du FH
    Yao Xue Xue Bao; 1990; 25(2):150-3. PubMed ID: 2173348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
    Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
    J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.
    Franchini C; Carocci A; Catalano A; Cavalluzzi MM; Corbo F; Lentini G; Scilimati A; Tortorella P; Camerino DC; De Luca A
    J Med Chem; 2003 Nov; 46(24):5238-48. PubMed ID: 14613326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of mexiletine on the excitability and vulnerability of the dog ventricle (author's transl)].
    Márquez Montes J; Vera Almazán A; Esteve Alderete JJ; Puente Rodero B; Montero C; Castillo-Olivares JL
    Arch Farmacol Toxicol; 1981 Dec; 7(3):307-18. PubMed ID: 7337470
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hemodynamic effects of lidocaine and mexiletine in acute heart infarction].
    Keltai M; Kékány P; Mádai A
    Z Gesamte Inn Med; 1982 Aug; 37(15):507-9. PubMed ID: 7148050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations of the haemodynamics of mexiletine.
    Banim SO; Da Silva A; Stone D; Balcon R
    Postgrad Med J; 1977; 53 Suppl 1():74-7. PubMed ID: 876956
    [No Abstract]   [Full Text] [Related]  

  • 14. [The anti-arrhythmic action of mexiletine: experimental study].
    Ciraolo O; Quartarone M; Corica F; D'Andrea Petrelli L; Barbera N; Ceruso D
    G Clin Med; 1983 Nov; 64(11):483-90. PubMed ID: 6667804
    [No Abstract]   [Full Text] [Related]  

  • 15. [Electrophysiologic actions of mexiletine (Kö-1173) in man].
    González Maqueda I; García Fernández F; Martín Jadraque L
    Med Clin (Barc); 1981 Mar; 76(5):223-5. PubMed ID: 7206892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics.
    Carlier J
    Acta Cardiol Suppl; 1980; (25):81-100. PubMed ID: 6966456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemodynamic effects of a new anti-arrhythmia agent: mexiletine].
    Tomassetti V; Fontana F; Masi M; Mezzetti A; Poggiopollini G; Cuppini A; Cuccurullo F
    Boll Soc Ital Cardiol; 1980; 25(1):95-100. PubMed ID: 7236434
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine.
    Middleton D
    Acta Cardiol Suppl; 1980; (25):45-53. PubMed ID: 6990666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemodynamic and electrophysiological effects of intravenous injection of mexiletine].
    Tanaka T; Kusumoto M; Umemura J; Miyazawa Y; Suwa J; Komatsu Y
    Kokyu To Junkan; 1983 Dec; 31(12):1355-60. PubMed ID: 6676806
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of mexiletine in the treatment of ventricular arrhythmia in patients with conduction disorders and sick sinus syndrome].
    González Zuelgaray J; Nieves E; Fernández R; Posse RA
    Medicina (B Aires); 1982; 42(5):483-7. PubMed ID: 7169943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.